DJS Law Group Investigates Corcept Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 02 2026
0mins
Should l Buy CORT?
Source: Newsfilter
- Investigation Background: DJS Law Group is investigating potential securities violations by Corcept Therapeutics, focusing on whether the company made misleading statements or failed to disclose critical information, which may have led to investor losses.
- FDA Response: On December 31, 2026, Corcept revealed that the FDA issued a Complete Response Letter regarding the New Drug Application for relacorilant, indicating that while the GRACE trial met its primary endpoint, the FDA required additional evidence of effectiveness, highlighting regulatory hurdles.
- Stock Price Impact: Following the FDA announcement, Corcept's shares plummeted by over 50%, reflecting a pessimistic market sentiment regarding the company's future prospects, which could undermine investor confidence.
- Legal Service Commitment: DJS Law Group emphasizes its focus on enhancing investor returns through balanced counseling and aggressive advocacy, showcasing its expertise in securities class actions and corporate governance litigation to support affected investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 33.300
Low
50.00
Averages
91.00
High
121.00
Current: 33.300
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to move for Lead Plaintiff in the ongoing securities class action is April 21, 2026, urging those who suffered significant losses to contact the firm promptly to protect their rights.
- False Statements Allegation: The lawsuit, Allegheny County v. Corcept, alleges that throughout the Class Period from 2024 to 2025, the company misled investors by failing to disclose FDA warnings regarding the efficacy of its lead drug candidate, relacorilant, leading to significant investor deception.
- Stock Price Crash: On December 31, 2025, Corcept revealed it received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 on December 30 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting extreme market pessimism about the company's future.
- Information Gap Issue: Reed Kathrein, a partner at Hagens Berman, highlighted that there is a significant information gap between what Corcept publicly stated and what the FDA communicated privately, which may have led investors to misjudge the company's prospects, exacerbating their losses.
See More
Corcept Lawsuit Reminder for Investors
- Lawsuit Deadline: Corcept (NASDAQ:CORT) investors are reminded that April 21, 2026, is the deadline to seek lead plaintiff appointment in the class action, with late applications not considered by the court, potentially jeopardizing investor rights in the litigation.
- FDA Response Letter: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter (CRL) indicating that the clinical evidence submitted was insufficient to support the NDA for relacorilant, causing a dramatic 50.4% drop in share price from $70.20 to $34.80 in a single day, severely impacting the company's market value.
- Clinical Trial Controversy: The lawsuit alleges that Corcept misrepresented the strength of its clinical trials as “powerful support” for the NDA, while the FDA had raised concerns about the adequacy of the clinical development program, which could lead to approval failures and diminish investor confidence.
- Subsequent Stock Price Fluctuation: Following the FDA's detailed concerns published on January 30, 2026, Corcept's stock price fell another 10.6%, from $44.61 to $39.87, exacerbating investor losses and highlighting the risks associated with the company's regulatory challenges.
See More
Corcept's Drug Application Rejected by FDA, Stock Plummets
- FDA Rejection: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter rejecting its New Drug Application for relacorilant due to insufficient evidence of effectiveness, causing the stock price to plummet by 50.42% to $34.80, directly impacting investor confidence.
- Class Action Lawsuit: A class action lawsuit has been initiated for shareholders who purchased Corcept stock between October 31, 2024, and December 30, 2025, alleging that the company failed to disclose FDA concerns, allowing investors until April 21, 2026, to file as lead plaintiffs for potential recovery.
- FDA Feedback Issues: The updated Complete Response Letter revealed that the FDA had repeatedly informed Corcept of inadequacies in its clinical development program prior to submission, indicating significant review issues, which were not disclosed to investors, exacerbating market anxiety.
- Company Outlook Deterioration: The FDA's rejection and subsequent stock decline severely undermine Corcept's business outlook, leading to a significant drop in investor confidence that may affect the company's future financing and research plans.
See More
Corcept Faces Securities Class Action Lawsuit
- Deadline for Lawsuit: ClaimsFiler reminds investors that those who purchased Corcept Therapeutics (Nasdaq: CORT) shares between October 31, 2024, and December 30, 2025, must file lead plaintiff applications by April 21, 2026, to protect their rights in the class action lawsuit.
- Legal Allegations: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which severely undermined investor confidence in the company's new drug application.
- FDA Response Letter: On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter regarding its new drug application, indicating it could not make a favorable benefit-risk assessment for relacorilant, further exacerbating market anxiety.
- Stock Price Plunge: Following this announcement, Corcept's stock price plummeted by 50.4%, from $70.20 on December 30, 2025, to $34.80 on December 31, directly impacting investors' financial positions and the company's market credibility.
See More
Corcept Therapeutics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP has alerted investors that a class action has been filed on behalf of those who purchased Corcept Therapeutics (NASDAQ:CORT) stock between October 31, 2024, and December 30, 2025, indicating significant legal risks that could undermine shareholder confidence.
- FDA Review Risks: The lawsuit alleges that Corcept misled investors regarding its New Drug Application (NDA) for relacorilant, claiming that clinical trials provided 'powerful support,' while in reality, the FDA expressed concerns about the adequacy of clinical evidence, potentially jeopardizing approval.
- Stock Price Plunge: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter (CRL), causing its stock price to plummet from $70.20 on December 30, 2025, to $34.80, a decline of 50.4%, directly impacting investor asset values.
- Shareholder Action Recommendations: Robbins LLP encourages shareholders to participate in the class action as lead plaintiffs, emphasizing that representation is available on a contingency fee basis, highlighting the importance of corporate governance and shareholder rights protection.
See More
Lawsuit Claims Management Concealed FDA Warnings on Data Issues
- Lawsuit Background: Hagens Berman reminds investors that the deadline to move for Lead Plaintiff in the securities class action against Corcept Therapeutics (NASDAQ:CORT) is April 21, 2026, allowing investors to seek recovery for their losses.
- Allegations Details: The lawsuit filed by Allegheny County Employees' Retirement System claims that Corcept failed to disclose FDA warnings regarding its lead drug candidate, Relacorilant, during the class period from October 31, 2024, to December 30, 2025, resulting in significant investor losses.
- Information Discrepancy: The lawsuit highlights a critical 'information gap' between what the company publicly stated and what the FDA reportedly communicated privately, potentially leading to misjudgments about the company's prospects and affecting stock value.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, thereby furthering the investigation into Corcept.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to move for Lead Plaintiff in the ongoing securities class action is April 21, 2026, urging those who suffered significant losses to contact the firm promptly to protect their rights.
- False Statements Allegation: The lawsuit, Allegheny County v. Corcept, alleges that throughout the Class Period from 2024 to 2025, the company misled investors by failing to disclose FDA warnings regarding the efficacy of its lead drug candidate, relacorilant, leading to significant investor deception.
- Stock Price Crash: On December 31, 2025, Corcept revealed it received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 on December 30 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting extreme market pessimism about the company's future.
- Information Gap Issue: Reed Kathrein, a partner at Hagens Berman, highlighted that there is a significant information gap between what Corcept publicly stated and what the FDA communicated privately, which may have led investors to misjudge the company's prospects, exacerbating their losses.
See More
Corcept Lawsuit Reminder for Investors
- Lawsuit Deadline: Corcept (NASDAQ:CORT) investors are reminded that April 21, 2026, is the deadline to seek lead plaintiff appointment in the class action, with late applications not considered by the court, potentially jeopardizing investor rights in the litigation.
- FDA Response Letter: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter (CRL) indicating that the clinical evidence submitted was insufficient to support the NDA for relacorilant, causing a dramatic 50.4% drop in share price from $70.20 to $34.80 in a single day, severely impacting the company's market value.
- Clinical Trial Controversy: The lawsuit alleges that Corcept misrepresented the strength of its clinical trials as “powerful support” for the NDA, while the FDA had raised concerns about the adequacy of the clinical development program, which could lead to approval failures and diminish investor confidence.
- Subsequent Stock Price Fluctuation: Following the FDA's detailed concerns published on January 30, 2026, Corcept's stock price fell another 10.6%, from $44.61 to $39.87, exacerbating investor losses and highlighting the risks associated with the company's regulatory challenges.
See More
Corcept's Drug Application Rejected by FDA, Stock Plummets
- FDA Rejection: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter rejecting its New Drug Application for relacorilant due to insufficient evidence of effectiveness, causing the stock price to plummet by 50.42% to $34.80, directly impacting investor confidence.
- Class Action Lawsuit: A class action lawsuit has been initiated for shareholders who purchased Corcept stock between October 31, 2024, and December 30, 2025, alleging that the company failed to disclose FDA concerns, allowing investors until April 21, 2026, to file as lead plaintiffs for potential recovery.
- FDA Feedback Issues: The updated Complete Response Letter revealed that the FDA had repeatedly informed Corcept of inadequacies in its clinical development program prior to submission, indicating significant review issues, which were not disclosed to investors, exacerbating market anxiety.
- Company Outlook Deterioration: The FDA's rejection and subsequent stock decline severely undermine Corcept's business outlook, leading to a significant drop in investor confidence that may affect the company's future financing and research plans.
See More
Corcept Faces Securities Class Action Lawsuit
- Deadline for Lawsuit: ClaimsFiler reminds investors that those who purchased Corcept Therapeutics (Nasdaq: CORT) shares between October 31, 2024, and December 30, 2025, must file lead plaintiff applications by April 21, 2026, to protect their rights in the class action lawsuit.
- Legal Allegations: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which severely undermined investor confidence in the company's new drug application.
- FDA Response Letter: On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter regarding its new drug application, indicating it could not make a favorable benefit-risk assessment for relacorilant, further exacerbating market anxiety.
- Stock Price Plunge: Following this announcement, Corcept's stock price plummeted by 50.4%, from $70.20 on December 30, 2025, to $34.80 on December 31, directly impacting investors' financial positions and the company's market credibility.
See More
Corcept Therapeutics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP has alerted investors that a class action has been filed on behalf of those who purchased Corcept Therapeutics (NASDAQ:CORT) stock between October 31, 2024, and December 30, 2025, indicating significant legal risks that could undermine shareholder confidence.
- FDA Review Risks: The lawsuit alleges that Corcept misled investors regarding its New Drug Application (NDA) for relacorilant, claiming that clinical trials provided 'powerful support,' while in reality, the FDA expressed concerns about the adequacy of clinical evidence, potentially jeopardizing approval.
- Stock Price Plunge: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter (CRL), causing its stock price to plummet from $70.20 on December 30, 2025, to $34.80, a decline of 50.4%, directly impacting investor asset values.
- Shareholder Action Recommendations: Robbins LLP encourages shareholders to participate in the class action as lead plaintiffs, emphasizing that representation is available on a contingency fee basis, highlighting the importance of corporate governance and shareholder rights protection.
See More
Lawsuit Claims Management Concealed FDA Warnings on Data Issues
- Lawsuit Background: Hagens Berman reminds investors that the deadline to move for Lead Plaintiff in the securities class action against Corcept Therapeutics (NASDAQ:CORT) is April 21, 2026, allowing investors to seek recovery for their losses.
- Allegations Details: The lawsuit filed by Allegheny County Employees' Retirement System claims that Corcept failed to disclose FDA warnings regarding its lead drug candidate, Relacorilant, during the class period from October 31, 2024, to December 30, 2025, resulting in significant investor losses.
- Information Discrepancy: The lawsuit highlights a critical 'information gap' between what the company publicly stated and what the FDA reportedly communicated privately, potentially leading to misjudgments about the company's prospects and affecting stock value.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, thereby furthering the investigation into Corcept.
See More
